PPS has entered into an agreement with BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, for cGMP production of BrainStorm's stem cell therapeutic product. The clinical-grade product will be used in a pre-clinical safety trial for the company’s innovative therapy for ALS.
“We are very excited that we are moving into this phase of product development with a highly-experienced contractor that will enable us to move rapidly ahead with the final stages of our ALS pre-clinical program” said Rami Efrati, CEO of BrainStorm Cell Therapeutics.
For further information please enter:
| 